Results 291 to 300 of about 12,785,139 (351)
, 2001 The differential diagnosis in the bleeding patient includes inhibitory antibodies to blood coagulation proteins. Factor VIII (fVIII) is the most commonly targeted coagulation protein by the immune system. FVIII inhibitors arise as alloantibodies in transfused hemophiliacs and as autoantibodies in nonhemophiliac populations (1, 2, 3, 4). They develop in
John F. Healey +3 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Haemophilia, 1998
Summary. The immunogenicity of factor VIII depends on the interaction of multiple parametres including host susceptibility and characteristics of the factor VIII preparations. We briefly review here the basic mechanisms by which tolerance to self is established, maintained, and possibly broken in the context of haemophilia A, with special emphasis on ...
C. A. Lee +6 more
openaire +3 more sources
Summary. The immunogenicity of factor VIII depends on the interaction of multiple parametres including host susceptibility and characteristics of the factor VIII preparations. We briefly review here the basic mechanisms by which tolerance to self is established, maintained, and possibly broken in the context of haemophilia A, with special emphasis on ...
C. A. Lee +6 more
openaire +3 more sources
Factor VIII activity and factor VIII related antigen in newborns [PDF]
European Journal of Pediatrics, 1978 Factor VIII procoagulant activity and factor VIII related antigen were examined in 20 full-term and preterm newborn infants during the first days of life. The control group involved 15 adults volunteers. Factor VIII activity was estimated by a one-stage test and factor VIII related antigen was determined by immunelectrophoresis according to Laurell ...
B. Scheidt, B. Maak, J. Frenzel
openaire +2 more sources
Scandinavian Journal of Haematology, 1984
New approaches and techniques for improving source material collection and factor VIII production at Blood Bank level have been reported recently. Heparin has shown to be of great importance in increasing both yield and stability of factor VIII in the purification and concentration process.
P. C. Das, C. Th. Smit Sibinga
openaire +3 more sources
New approaches and techniques for improving source material collection and factor VIII production at Blood Bank level have been reported recently. Heparin has shown to be of great importance in increasing both yield and stability of factor VIII in the purification and concentration process.
P. C. Das, C. Th. Smit Sibinga
openaire +3 more sources
Autoimmunity Reviews, 2002
Anti-Factor VIII (FVIII) antibodies represent a unique model to study the relationship between natural autoreactivity (natural antibodies to FVIII of healthy individuals) and disease-associated autoimmunity ('spontaneous' FVIII inhibitors of patients with anti-FVIII autoimmune disease) to a single human protein antigen.
Michel D. Kazatchkine +5 more
openaire +3 more sources
Anti-Factor VIII (FVIII) antibodies represent a unique model to study the relationship between natural autoreactivity (natural antibodies to FVIII of healthy individuals) and disease-associated autoimmunity ('spontaneous' FVIII inhibitors of patients with anti-FVIII autoimmune disease) to a single human protein antigen.
Michel D. Kazatchkine +5 more
openaire +3 more sources
Haemophilia, 1995
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire +6 more sources
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire +6 more sources
Antihemophilic Factor (Factor VIII)
Annals of Internal Medicine, 1978Antihemophilic factor (Factor VIII) is an agent in normal plasma that corrects the coagulative defect of classic hemophillia. The plasma of hemophiliacs contains normal amounts of a variant of antihemophilic factor deficient in clot-promoting properties. In contrast, von Willebrand's disease is usually associated with a true deficiency of this protein.
openaire +3 more sources
FACTOR VIII AND GLOMERULONEPHRITIS
The Lancet, 1975To find out if determination of factor VIII,which most probably is synthetised in the intima of blood-vessesls, is of value for predicting the severity of vessel damge in glomerulonephritis, factor-VIII activity, factor-VIII-related antigen, and glomerular filtration-ratewere esto,ated om 85 patients with early glomerulonephritis on admission, and in ...
I. M. Nilsson, M. Ekberg
openaire +3 more sources
Activation, activity and inactivation of factor VIII in factor VIII products
Haemophilia, 2016IntroductionFactor VIII (FVIII) products used in haemophilia A treatment show inter‐and intra‐product and inter‐assay differences in specific activity. The mechanistic basis of these differences remains unclear.AimThe aim of this study was to mechanistically compare the functional properties of an in‐house excipient‐free full‐length FVIII standard and ...
R. Elsman +4 more
openaire +3 more sources
SUPPRESSION OF FACTOR VIII ANTIBODY BY COMBINED FACTOR VIII AND CYCLOPHOSPHAMIDE
Acta Medica Scandinavica, 1974Abstract. Four patients with severe haemophilia A complicated by inhibitors of factor VIII (corresponding to 0.5, 0.7, 1.0 and 2.5 U/ml plasma) and a non‐haemophilic woman with an acquired inhibitor of factor VIII (corresponding to 160 U/ml plasma) have been treated with a large single dose of factor VIII concentrate (4 000–8 000 U factor VIII) and ...
Inga Marie Nilsson +2 more
openaire +3 more sources